{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:49:07Z","timestamp":1760233747785,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma is a severe and life-threatening malignancy derived from melanocytes. The traditional treatment for melanoma could not sustain satisfactory outcomes long term; however, the recent immune checkpoint treatment has made a breakthrough in these problems. Nivolumab is a representative immune checkpoint treatment, and this PD-1-targeted therapy has evolutionally developed and improved the clinical outcome in a recent decade. On the other hand, the clinical application of immune checkpoint treatment presents clinicians with novel questions, especially how to obtain additional efficacy and overcome the disadvantage by using this treatment. To answer these problems, we first investigated the distribution of PD-L1 in various organs to clarify the organs most affected by anti-PD-1 antibody treatment. Among various organs, lung, placenta, spleen, heart, and thyroid highly expressed PD-L1, while skin, thalamus, hippocampus, ovary, stomach, testis, and prostate showed lower expressions of PD-L1. Furthermore, the immune profiles were also examined in tumors and peripheral blood in patients with melanoma. PD-1 was highly expressed in CD8 and CD4 cells, and B cells also highly expressed PD-1 compared with NK cells. However, there was no significant difference in Th1\/Th2\/Th17 cytokines and inhibitory cytokine IL-10. Although nevus showed a low expression of PD-L1 compared with healthy skin, PD-L1 expression was increased in growth-phase melanoma. Finally, we analyzed the peripheral blood profiles in patients treated with nivolumab. PD-1-bearing dendritic cells (DCs) were increased during nivolumab treatment and Lin-CD11c+HLA-DR+ cells were highly increased during nivolumab treatment. These findings indicate a clue to answering the problems during nivolumab treatment and suggest to us the importance of multiple aspect observation during immune checkpoint treatment.<\/jats:p>","DOI":"10.3390\/ijms22041957","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T08:09:09Z","timestamp":1613462949000},"page":"1957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma"],"prefix":"10.3390","volume":"22","author":[{"given":"Ryuichi","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health 1-1, Iseigaoka, Yahatanishi-Ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health 1-1, Iseigaoka, Yahatanishi-Ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motonobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health 1-1, Iseigaoka, Yahatanishi-Ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jid.2019.08.002","article-title":"The evolution of melanoma\u2014Moving beyond binary models of genetic progression","volume":"140","author":"Zeng","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Kim","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_6","first-page":"141","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1\u2013PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.4049\/jimmunol.177.3.1670","article-title":"New generation vaccine induces effective melanoma-specific CD8+T cells in the circulation but not in the tumor site","volume":"177","author":"Appay","year":"2006","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1089\/hum.1996.7.16-1955","article-title":"Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells","volume":"7","author":"Arienti","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.161.8.4183","article-title":"Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination","volume":"161","author":"Lee","year":"1998","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.4049\/jimmunol.164.11.6057","article-title":"High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene","volume":"164","author":"Baurain","year":"2000","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603763","article-title":"Mechanisms of local immunosuppression in cutaneous melanoma","volume":"96","author":"Polak","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1042-3680(02)00017-7","article-title":"Pituitary anatomy and physiology","volume":"14","author":"Amar","year":"2003","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1210\/jcem-9-2-149","article-title":"The mechanism of the secretion of thyroid hormone","volume":"9","author":"Leblond","year":"1949","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/edrv-11-1-5","article-title":"Measurement of free hormones in blood","volume":"11","author":"Ekins","year":"1990","journal-title":"Endocr. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102560"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: Case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2147\/OTT.S62102","article-title":"Nivolumab in the treatment of malignant melanoma: Review of the literature","volume":"8","author":"Nakamura","year":"2015","journal-title":"OncoTargets Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"Riella","year":"2011","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res. Part B Dev. Reprod. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002371-200407000-00003","article-title":"Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes","volume":"27","author":"Perricone","year":"2004","journal-title":"J. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/intimm\/dxv034","article-title":"Regulatory B cells in anti-tumor immunity","volume":"27","author":"Zhang","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0647-5","article-title":"Prognostic value of B cells in cutaneous melanoma","volume":"11","author":"Selitsky","year":"2019","journal-title":"Genome Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/106161299320316","article-title":"Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK","volume":"8","author":"Tam","year":"1999","journal-title":"J. Hematother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ijc.10395","article-title":"Overexpression of interleukin-15in vivo enhances antitumor activity against mhc class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response","volume":"99","author":"Yajima","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.21873\/anticanres.11450","article-title":"Multi-omics profiling of patients with melanoma treated with nivolumab in project HOPE","volume":"37","author":"Yoshikawa","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipili-mumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-020-02497-9","article-title":"Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients","volume":"69","author":"Kasanen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1248327","DOI":"10.1080\/2162402X.2016.1248327","article-title":"Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients","volume":"5","author":"Nonomura","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/intimm\/dxx073","article-title":"Clinical response to PD-1 blockade cor-relates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma","volume":"30","author":"Takeuchi","year":"2018","journal-title":"Int. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to An-ti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41416-018-0363-8","article-title":"Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/1346-8138.14643","article-title":"Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab","volume":"45","author":"Saito","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-12-0292","article-title":"Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia\/lymphoma","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"She, X., Rohl, C.A., Castle, J.C., Kulkarni, A.V., Johnson, J.M., and Chen, R. (2009). Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-269"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4161\/cbt.4.9.2165","article-title":"Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi\/melanoma in situ and advanced-stage melanomas","volume":"4","author":"Smith","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1541-7786.MCR-07-0344","article-title":"Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases","volume":"6","author":"Xu","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Critchley-Thorne, R.J., Yan, N., Nacu, S., Weber, J., Holmes, S.P., and Lee, P.P. (2007). Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040176"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:52Z","timestamp":1760160292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041957"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041957","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}